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Abstract
Clobazam (CLB) is an older anti-epileptic
drug, with a slightly different chemical struc-
ture from that of the classic benzodiazepines
currently used in the treatment of epilepsy,
which confers less sedative properties in terms
of negative adverse effects. It is also thought to
be better tolerated than other anti-epileptic
drugs, whilst maintaining a very similar level
of efficacy. It has been tested extensively in
over 50 studies on more than 3000 patients
with epilepsy and is now approved as an
adjunctive treatment of epilepsy in >100 coun-
tries. The aim of this review is to evaluate sev-
eral existing studies on the effectiveness of
CLB as an adjunctive therapy in the treatment
of epilepsy and whether this therapy is more
useful in particular types of epilepsy or seizure
prevention. This is not a systematic review but
a general overview of some of the most recent
studies on the effectiveness of CLB as an
adjunctive therapy. Additionally, the benefits of
having an oral suspension of CLB will be eval-
uated with regards to patient groups benefit-
ing from this formulation. The last issue
addressed is that of the importance of pre-
scribing CLB by brand, along with the benefits
and risks of not doing so.
The use of clobazam as anadjunct therapy in the treat-ment of epilepsy 
Clobazam (CLB) is a 1,5-benzodiazepine
that has been introduced in 1975 as an anxi-
olytic drug and shortly after,1,2 it was discov-
ered that it has strong anti-epileptic properties
as well. It is distinguished from other classic
1,4-benzodiazepines in that its nitrogen atoms
are placed in 1st and 5th positions in the B ring.
Its mechanism of action is similar to other
benzodiazepines however CLB is believed to be
a partial agonist rather than non-selective full
receptor agonists, which is what 1,4-benzodi-
azepines are.3 Moreover, CLB has lower affini-
ty for the GABAa subunits and greater selectiv-
ity for a2 subunits over a1 subunits, than the
1,4-benzodiazepines and it is thought that
these properties confer to CLB less sedative
effects than other benzodiazepines.2,4
The standard treatment for epilepsy involves
using a single anti-epileptic drug at the mini-
mally effective dose, up to the maximum toler-
ated dose.5 However, the numerous seizure
types that a patient may experience render
treatments with one agent ineffective so com-
bination therapy is often required.
Breakthrough seizures are often experienced
by patients; hence continuous adjustments
need to be made to their medications regimes
over the course of their lifetime, both in terms
of dosage and number of agents used.2
Due to its less sedative effects and its very
similar effectiveness in comparison with other
agents, CLB is very frequently selected as an
add-on agent when polytherapy is needed, par-
ticularly in the case of intractable epilepsy.
Several studies have shown that CLB is an
effective adjunctive anti-epileptic drug (AED)
for a few specific types of epilepsy, most impor-
tantly Lennox-Gastaut syndrome (LGS). These
include both retrospective studies and more
importantly randomized, double-blind studies. 
A randomized, double-blind, dose-ranging
study evaluated safety and efficacy of CLB as
adjunctive therapy for drop seizures in
patients with LGS.6 LGS is an epileptic
encephalopathy characterized by multiple
types of seizures and developmental delay. The
presence of a characteristic triad described
typical LGS: i) tonic axial, atonic, and/or atypi-
cal absence seizures; ii) electroencephalogra-
phy (EEG) abnormalities with bursts of diffuse
slow spike-wave pattern of 1.5-2.5 Hz; and iii)
impaired intellectual growth. Atonic or drop
seizures are frequent in patients with LGS and
are responsible for most injuries associated
with falls. Seizures in LGS are refractory to
most AEDs hence the need for combinational
therapy.6
The study conducted was a phase II, ran-
domized, double-blind, dose-ranging multicen-
ter study which comprised a 4-week baseline
period, a 3-week titration period and a 4-week
baseline period.6 A daily seizure diary record
was used to record the number of seizures,
specifically any drop seizures. They were
recorded as single drop seizures (defined as a
drop seizure occurring 15 min or more before
and after the next seizure or cluster) or as
clusters (defined as two or more drop seizures,
with less than 15 min between any two consec-
utive seizures); non-drop seizures have also
been recorded but on a smaller number of
patients. Six weight groups have been defined
and patients with two or more drop seizures
per week during the baseline period were
placed in one of six weight groups and ran-
domly assigned to either low-dose CLB (target
dose of 0.25 mg/kg/day; maximum 10 mg/day if
weight was lower than 37.6 kg) or high-dose
CLB (target dose of 1.0 mg/kg/day; maximum
40 mg/day if weight was higher than 37.6 kg).
A significant reduction in drop seizure rates
was observed both in the low-dose group
(mean reduction=12%; P=0.0162) and in the
high-dose group (mean reduction=85%;
P<0.0001). Importantly, high-dose CLB was
significantly more effective in reducing drop
seizure rates compared with low-dose CLB
(P<0.0001). Eighty-nine percent of responders
in the high-dose group and 56% in the low-
dose group experienced a ≥25% reduction in
drop seizures (P=0.0025); 83 and 38% experi-
enced a ≥50% reduction (P=0.0001); 67 and
25% experienced a ≥75% reduction
(P=0.0006); and 6 and 22% experienced a
100% reduction (P=0.0629). The study showed
that CLB reduces the non-drop seizure rates as
well, particularly in the high-dose group. The
percent change in the low-dose group was not
significant, however in the high-dose group
the percent change from baseline (59±55%,
n=22) was significant. The dose-dependent
manner of reducing drop seizure rates was
also recorded for non-drop seizure rates, the
reduction being significantly greater in the
high-dose group compared with the low-dose
group (P=0.0222). Parent/caregiver and inves-
tigator global evaluations have both demon-
strated that the high-dose CLB group showed
significantly greater improvements in overall
symptoms compared to low-dose CLB group. At
one investigation site, the quality of life of four
children receiving CLB was greatly improved,
as they discontinued wearing helmets and
therefore they were able to move freely with-
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out the constant adult supervision previously
needed to prevent injury from drops.6
A more advanced phase III, double-blind,
placebo-controlled study on the safety and effi-
cacy of CLB in patients with LGS aged 2-54 was
conducted at 51 sites in the United States,
India, Europe and Australia between August
2007 and December 2009 and further assessed
CLB’s role as adjunctive therapy.7 This study
evaluated the efficacy of 3 CLB dosages in
decreasing weekly frequencies of drop and
total seizures and also assessed its safety
when administered ≥18 weeks at these 3
dosages. Patients aged 2-60 years were eligible
to participate if they had onset of LGS before
11 years age and currently weighed ≥12.5 kg.
The study included 4-week baseline, 3-week
titration and 12-week maintenance periods,
followed by either continuation in an open-
label study or a 2- or 3- week taper period.
Patients were randomly assigned to one of 4
groups, depending on weight (12.5 kg to ≤30
kg, >30 kg): i) placebo; ii) low-dosage CLB: tar-
get of 0.25 mg/kg/day (maximum, 10 mg/day);
iii) medium-dosage CLB: target of 0.5
mg/kg/day (maximum, 20 mg/day); or iv) high-
dosage CLB: target of 1.0 mg/kg/day (maxi-
mum, 40 mg/day). The mean patient age was
12.4 years. Importantly, approximately 50% of
all patients were receiving concomitant val-
proic acid, valproate semisodium, or valproate
sodium. 
The mean percentage decrease in average
weekly rate of drop seizures from baseline to
maintenance period was 12.1% for placebo vs
41.2% (P=0.0120), 49.4% (P=0.0015) and
68.3% (P<0.0001) for the 0.25, 0.50 and 1
mg/kg/day dosage groups respectively. Mean
difference from the placebo group increasing
with increasing CLB dosage (mean differences
of 29.1, 37.3 and 56.1% for the low, medium
and high respectively). A linear trend has been
noted in that increasing dosage of CLB lead to
increased efficacy in reducing the drop seizure
rates (P<0.0001). The mean percentage
decrease in average weekly rate of total (drop
and non-drop) seizures was 9.3% for placebo
vs 34.8% (P=0.0414), 45.3% (P=0.0044), and
65.3% (P<0.0001) for the CLB 0.25-, 0.5-, and
1.0-mg/kg/day groups. 
A 40.0% decrease in the average weekly rate
of non-drop seizures was observed for the
high-dosage group, however this was not sta-
tistically significant by analysis of covariance
model. An increase of 76.3, 53.3 and 3.3% has
been noted in the average weekly rate of non-
drop seizures for the placebo, low-dosage and
medium-dosage CLB group. 
Increasing CLB dosage lead to increase
response rates in patients with LGS. The per-
centage of patients with ≥50% decrease from
baseline to maintenance period in average
weekly rate of drop seizures was 31.6% for
placebo, 43.4, 58.6 and 77.6% for the low-,
medium-, and high-dosage CLB groups,
respectively. In comparison with the placebo
group, the likelihood of achieving ≥50%
response was greater for the medium-dosage
and high-dosage CLB groups.  Seizure-free
patients have also been reported: 2 patients in
the placebo group (3.5%) were seizure-free,
compared with 4 (7.5%), 7(12.1%) and 12
(24.5%) patients for the low-, medium-, and
high-dosage CLB groups.
Global evaluations of patients’ overall
changes in symptoms from physicians and
caregivers during the observed period have
also shown the CLB as adjunctive therapy led
to improvements: percentages of patients who
were at least minimally improved range from
71.2 to 80.7% (physicians’ assessments) and
79.2 to 81.6% (caregivers’ assessments) for
CLB vs 47.3 and 45.5% respectively for placebo.
Although retrospective studies are statisti-
cally less significant than randomized con-
trolled trials, they still provide valuable infor-
mation about the effectiveness and safety of
CLB in patients with epilepsy. A retrospective
study was conducted between January 2013
and January 2015 in patients suffering from
status epilepticus (SE). SE is defined as
seizures lasting >5 min or multiple seizures
without recovery of consciousness in between.
Refractory status epilepticus (RSE) is defined
as SE that persists despite adequate treatment
with benzodiazepines and at least one AED, or
SE requiring general anesthesia. About 12-
43% of the cases with SE become refractory,
and 50% of those requiring anesthesia will
become super-refractory. Patients from all age
groups in whom CLB was administered for the
management of SE were included in the study.
Over a period of 24 months, 17 patients
received CLB for the treatment of RSE. In all
these patients, CLB was used as add-on thera-
py after failure of two or more AEDs in ade-
quate dosing and it was the last AED added in
94% of the patients. Thirteen patients reported
a successful response to CLB (76.5%).8
Another retrospective study conducted at
the Hospital de Clínicas da Unicamp on 97
patients ranged 15 to 70 years who were evalu-
ated for surgery and had been followed-up for
≥1 year has evaluated the effectiveness of CLB
as add-on therapy. Of these 97 patients, 74.2%
had temporal lobe epilepsy, 8.2% had extra-
temporal epilepsy and in 17.6% patients the
epileptic syndrome could not be identified.
CLB was introduced after previous failure of at
least two mono-therapies, with carbamezap-
ine, phenytoin or valproate used up to maxi-
mum tolerated dose. The dosage of CLB ranged
from 10 to 60 mg twice a day and the period of
usage ranged from 1 month to 7 years and 9
months. The study brought proof to the effec-
tiveness of CLB as adjunctive therapy: 7.2%
patients were seizure-free, 49.4% had ≥50%
improvement in seizure control and 40.2%
patients had <50% improvement in seizure
control. In 3.1% no data were available.9
A review study conducted in 2011 evaluated
several studies on the effectiveness of CLB,10
both prospective and retrospective studies. In
pediatric patients with refractory epilepsy, six
open-label prospective studies have shown
that at least 54%-85% of patients experienced
at least a 50% drop in seizure rates (Table
1).6,7,11-20
Additionally, two retrospective studies have
also reported significant decrease in seizure
rates for pediatric patients using CLB as add-
on therapy (Table 1).11,17
Clinical studies of LGS were identified in a
2009 Cochrane review and by electronic data-
base search and indirect comparison of the rel-
ative efficacies of CLB, felbamate, lamotrigine,
topiramate and rufinamide as adjunctive treat-
ments for LGS was performed. These indirect
comparisons were performed by transforming
the primary efficacy endpoint from each trial
into Cohen’s d effect size. The results have
also shown that high-dosage CLB (1.0
mg/kg/day) was the most effective vs placebo,
whereas medium-dosage CLB (0.5 mg/kg/day)
and rufinamide had moderate effects.
Felbamate, lamotrigine and topiramate had
low effect sizes. Numbers of total seizures and
tonic-atonic seizures (drop attacks) were indi-
rectly compared and both comparisons proved
that medium- and high-dosage CLB are superi-
or to the other adjunctive LGS therapies.21
A study that investigated potential drug
interactions between CLB and other AEDs,
including phenytoin, phenobarbital, carba-
mazepine, valproate, lamotrigine, felbamate,
and oxcarbazepine, found no clinically mean-
ingful drug pharmacokinetic interactions,
which makes this drug suitable for the man-
agement of LGS as an adjunctive therapy due
to its pharmacokinetic properties and less
aggressive side effects.22
Why should clobazam be pre-scribed by brand?
The prescription of anti-epileptic medica-
tion can become an issue in the treatment of
epilepsy. Practitioners are often encouraged to
prescribe the cheapest drugs available and this
is often inappropriate for the management of
epilepsy.23 A research study conducted in 2003
suggests that even small differences between
two versions of the same drug can become very
problematic for the patient who is switching
them.23 Crawford et al. suggest that these prob-
lems include additional side-effects or
seizures frequency.24 However, the necessity of
prescribing CLB by brand is a hypothesis based
on the available evidence on other AEDs. 
The claimed advantage of prescribing gener-
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ically is that large amounts of money can be
saved. However, the hidden consequences of
generic prescribing is that costs may actually
increase due to increased doctor visit (as a
result of patient anxiety), increased sick leave,
worse health for the patient and even in some
cases potential loss of employment (Table 1).23
A survey of 1851 patients with epilepsy con-
ducted by Epilepsy Action revealed that in the
previous year, 33% of responders were given a
different version of brand of their regular AED.
Of these, almost 25% experienced an increase
in seizure frequency as a result and 33% expe-
rienced more or distinct side effects from the
ones previously experienced.23
The survey also showed that a significant
number of people (24%) reported that they
received a variety of versions of their medica-
tion in one single prescription.23
The recommended guideline from he
National Institute for Health and Care
Excellence (NICE) with regards to this issue
states as follows: Changing brand of AED is not
recommended due to variances in bioavailabil-
ity/ difference in pharmacokinetic profiles,
which leads to increased potential for reduced
effect or excessive side-effects (NICE, 2004).25
Patient’s anxiety is a factor of major impor-
tance in epilepsy, as it can easily trigger
seizures. Patients with changed medication
may be anxious to take them, which in turn
may lead to the loss of seizure control.
Suffering a seizure after a long seizure-free
period could have dramatic consequences on
the well being of the patient, both in terms of
the impact it has on his life but also in terms
of the damage a seizure can cause itself. The
impact that a slightly different version of an
AED can have on a patient’s life is to be taken
into consideration and must not be underesti-
mated.25,26
What patient groups may ben-efit most from a prescriptionof clobazam?
The NICE recommends CLB as an adjunctive
treatment where first-line antiepileptic drug
have failed.27
NICE recommends CLB as an adjunctive
treatment option for seizures: i) focal seizures;
ii) generalized tonic-clonic seizures; and
epilepsies: i) benign epilepsy with centrotem-
poral spikes; ii) Panayiotopoulous syndrome;
iii) late-onset childhood occipital epilepsy
(Gastaut type); iv) Dravet syndrome; v) epilep-
sy with generalized tonic-clonic seizures only.
NICE recommends CLB as an option on
referral to tertiary care for seizures: i) gener-
alized myoclonic seizures; ii) generalized
absence seizures; and epilepsies: i) childhood
absence epilepsy or other absence epilepsy
syndromes; ii) juvenile absence epilepsy or
other absence epilepsy syndromes; iii) juve-
nile myoclonic epilepsy; iv) idiopathic general-
ized epilepsy.
What patient groups may ben-efit most from a licensed liquidformulation of clobazam?Accurate dosingChildren
The ability to prescribe and administer safe
and accurate doses of anti-epileptic drugs is
fundamentally important in the treatment of
epilepsy. The potential, however, for dosing
accuracy in young children using CLB tablets
is limited, as the smallest dose that can be
accurately administered is 5 mg; it is for this
reason that CLB tablets are not licensed for
children under 6 years of age. Children
between the age of 1 month and 6 years
require small, weight-based doses, beginning
at 125 mcg/kg twice a day. CLB oral suspension
allows for the simple measurement of accurate
doses, which will support compliance and offer
the opportunity for optimal seizure control.Other patient groups
CLB suspension may be beneficial for
patients who require small starting doses of
CLB (doses <5 mg), for example elderly
patients or in those known to be poor CYP
2C19 metabolizers.Ease of administration
Swallowing difficulties (or the inability to
tolerate solid oral dosage forms) are over-rep-
resented in both adults and children with
severe seizure disorders. Known risk factors
for refractory epilepsy includes diffuse brain
injury, genetic and metabolic disorders and
underlying brain abnormalities, all of which
are likely to be associated with additional neu-
rological and/or behavioral deficit that may
preclude, or at least complicate, dosing with
solid oral dosage forms. Oral CLB suspension
offers these patients a more acceptable formu-
lation, which removes the need to crush
tablets, saving patient/caregiver time, while
potentially supporting compliance. The scien-
tific evidence backing the administration of
CLB orally is lacking, however this is a prag-
matic recommendation that can benefit a lot of
patients who have swallowing difficulties.Anxious patients
While epilepsy represents the majority of
CLB prescribing, it is also used in the short-
term treatment of anxiety in adults, where it is
reserved for the management of anxiety that is
severe, disabling or subjecting the individual
to unacceptable distress. Although drug
administration in this patient group might not
pose the same complexity as is associated with
the epileptic group this is, none-the-less, a
severely unwell cohort for whom compliance
may be compromised and for whom availability
of CLB oral suspension is advantageous. This
group is likely to include some elderly patients,
for whom the possibility of using smaller doses
would be desirable.
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